L’organisation Global Drug Survey (GDS), une compagnie de recherche indépendante basée à Londres, vient de rendre disponible les résultats de son enquête spéciale sur la consommation de substances pendant la pandémie de COVID-19.
Source: GDS
The GDS Special Edition on COVID-19 was developed as part of a global effort to better understand the impact of the pandemic on people’s lives with a specific focus on the use of alcohol and other drugs, mental health and relationships. Over 55,000 people took part. The survey ran for 7 weeks in (May – June 2020).
Table des matières des résultats disponibles:
- Page 1: Demographics
- Page 2: COVID-19 experiences & perceptions
- Page 3: Mental health status
- Page 4-5: Changes in alcohol use & gender
- Page 6: Increases in alcohol use since before COVID-19 & mental health diagnoses
- Page 7: Decreases in alcohol use since before COVID-19 & mental health diagnoses
- Page 8: Context of drinking alcohol
- Page 9: Other drugs: Use & changes
- Page 10: Increases in cannabis use & mental health
- Page 11: Decreases in cannabis use & mental health
- Page 12: Context of using cannabis
- Page 13: Decreases in cocaine & MDMA use since before COVID-19
- Page 14: Drug market shifts
- Page 15: Harm reduction information & strategies
- Page 16: Police encounters
- Page 17: Relationship & intimate partner abuse
Il est aussi possible d’obtenir des données par pays, pour les pays suivants: Australie, Autriche, Brésil, France, Allemagne, Irlande, Pays-Bas, Nouvelle-Zélande, Suisse, Grande-Bretagne, États-Unis.
Pour en savoir plus, consultez l’édition spéciale COVID-19 sur le site de GDS (en anglais)